These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
    Author: Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP.
    Journal: J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269.
    Abstract:
    OBJECTIVE: Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. METHODS: Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. RESULTS: In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. CONCLUSION: RTX was well tolerated with good clinical efficacy in patients with refractory AAV.
    [Abstract] [Full Text] [Related] [New Search]